Created in 1997
NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON is using its proprietary class of drugs, “Spiegelmers”, to target the tumor microenvironment, the new frontier in cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners,Edmond de Rothschild Investment Partners, DEWB, NGN ans Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany.